What is our purpose?

Our mission as the Sqail team is to combat the global problem of people suffering from diabetic sensory-motor peripheral neuropathy (DSPN), which affects more than 100 million diabetics worldwide, and to support these patients in their lives with the help of medical products. The main problems these patients face are loss of balance due to loss of peripheral sensitivity and severe pain due to neuropathic pain syndrome. That’s why we developed Wingo!

Why did we develop Wingo?

Wingo is a revolutionary bionic therapy and aid based on three pillars, building on the findings of the 2021 Nobel Prize in Medicine and the innovations of the founders of Sqail, and is now being launched on the market. Wingo, as a bionic medical product, treats gait disorders in neurological deficits. Lost sensitivity is restored, pain is relieved, walking safety is regained, and the risk of falling and the fear of falling are reduced. Wingo promotes an active life with increased mobility, continuous muscle development, and improved long-term blood sugar regulation.